Legal & RegulatoryEvent: September 4, 2026
BIAT GROUP announced that Tetraneuron received approval for its first-in-human clinical testing in Alzheimer’s disease.
Published
Signal category
Legal & Regulatory
Quote
“Tetraneuron for the approval of its first-in-human clinical testing in Alzheimer’s disease”
— Rosa M Osuna Aguilar|BIAT GROUP team
Company
BIAT GROUP
Biotech Corporate Group devoted to Develop Next-Generation Solutions for Global Health. Listed "BST" in BME-Growth.
- Location
- Jerez de la Frontera, ES
- Company size
- 17 employees
Biat Group develops and commercializes biotech assets, mainly new approach methods (NAMs) for in-vivo toxicity and efficacy regulatory and non-regulatory testing and proprietary split-inteins with unique applications in advanced therapies among others